Congruence Therapeutics has announced the closing of a $39.5 million financing to support the advancement of its pipeline of small molecule correctors targeting diseases caused by protein misfolding. The financing round was co-led by Dimension and OrbiMed, with participation from Amplitude Ventures, FSTQ, Lumira Ventures, Investissement Québec, BDC Capital, Driehaus Capital Management, and Silver Arc.
The company will use the proceeds to advance its lead program, CGX-926, which is currently in a Phase 1/1b clinical trial for MC4R-deficient genetic obesity. The study is evaluating the therapy in both healthy subjects and patients with the condition. In parallel, Congruence plans to complete IND-enabling activities for two additional programs targeting GBA1-driven Parkinson’s disease and Alpha-1 antitrypsin deficiency, with regulatory filings expected in early 2027.
Congruence’s approach focuses on correcting protein misfolding at the molecular level using small molecules designed through its proprietary Revenir™ platform. This computational drug discovery engine analyzes protein dynamics and identifies novel binding opportunities, enabling the development of therapies aimed at restoring normal protein function across a range of genetically validated targets.
Beyond its internal pipeline, the company is also expanding its collaborative efforts, including an extended multi-target partnership with Ono Pharmaceutical. This collaboration spans therapeutic areas such as oncology, neurology, and immunology. Congruence is also working with another global pharmaceutical partner on a metabolic disease target.
KEY QUOTES:
“Our mission is to translate biology, chemistry and protein structural insights into medicines that address disease at its molecular origin. In addition to CGX-926, we are advancing multiple proprietary and collaborative programs. We thank our new and existing investors for their continued support.”
Clarissa Desjardins, Co-Founder And CEO, Congruence Therapeutics
“Leveraging cutting edge molecular dynamics and machine learning, Congruence has built a best-in-class platform to unlock an exciting modality of medicines in small molecule correctors. In short order Clarissa and team have demonstrated technology and scientific leadership, joined with strong execution and capital efficiency. This is the promise of technologically enabled biotech. We’re thrilled to join as CGX-926 enters the clinic and we see the translation of the platform’s unique capabilities.”
Zavain Dar, Founder And Managing Partner, Dimension
